{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:15:47Z","timestamp":1761862547145},"reference-count":31,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: The impairment of renal function can affect the clinical presentation of primary hyperparathyroidism (PHPT), increasing cardiovascular morbidity, fracture rate, and the risk of mortality.<\/jats:p>\n               <jats:p>Aim: The aim of the study was to assess the differences in bone status in a series of consecutive patients affected by PHPT without overt renal failure at diagnosis grouped according to creatinine clearance (Ccr).<\/jats:p>\n               <jats:p>Methods: A total of 161 consecutive patients with PHPT were studied. They were divided into two groups based on Ccr. Group A had Ccr 70 ml\/min or less (n = 49), and group B had Ccr greater than 70 ml\/min (n = 112). PTH, total and ionized serum calcium; urinary calcium and phosphate; serum 25-hydroxyvitamin D3; serum and urinary bone markers; lumbar, forearm, and femoral bone mineral density (BMD) were evaluated.<\/jats:p>\n               <jats:p>Results: Patients in group A were older than those in group B (P &amp;lt; 0.0001). PTH levels did not differ in the two groups, whereas both urinary calcium and phosphorus were lower in group A than group B (P &amp;lt; 0.01). Lower BMD was evident in group A at lumbar spine (P &amp;lt; 0.002), forearm (P &amp;lt; 0.0001), and femur (P &amp;lt; 0.01). In asymptomatic PHPT, those with Ccr 70 ml\/min or less had lower forearm BMD than patients with higher Ccr (P &amp;lt; 0.00001). When adjusting for age and body mass index in PHPT, BMD at each site persisted being lower (P &amp;lt; 0.05) in group A than group B. In all PHPT subjects, Ccr (beta = 0.29, P &amp;lt; 0.0005), age (beta = \u22120.27, P &amp;lt; 0.00001), and PTH levels (beta = \u22120.27, P &amp;lt; 0.0005) were all independently associated with forearm BMD.<\/jats:p>\n               <jats:p>Conclusions: In PHPT a slight decrease in renal function is associated with more severe BMD decrease, independent of age, body mass index, and PTH levels. This association is also present in asymptomatic PHPT and strengthens the National Institutes of Health recommendations for surgery in patients with mild PHPT.<\/jats:p>","DOI":"10.1210\/jc.2006-0070","type":"journal-article","created":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T09:00:19Z","timestamp":1149066019000},"page":"3011-3016","source":"Crossref","is-referenced-by-count":26,"title":["A Slight Decrease in Renal Function Further Impairs Bone Mineral Density in Primary Hyperparathyroidism"],"prefix":"10.1210","volume":"91","author":[{"given":"Laura","family":"Gianotti","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Cesario","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pia","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Razzore","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Magro","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Piovesan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Oncology (A.Pio.) S. G. Battista Hospital, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Borretta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (L.G., F.T., F.C., A.Pia, P.R., G.M., G.B.), S. Croce and Carle Hospital, 12100 Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613322757800_R1","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMcp032200","article-title":"Asymptomatic primary hyperparathyroidism","volume":"350","author":"Bilezikian","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071613322757800_R2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2004.01422.x","article-title":"Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features","volume":"257","author":"Bilezikian","year":"2005","journal-title":"J Int Med"},{"key":"2020071613322757800_R3","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/jc.2003-031014","article-title":"Incipient primary hyperparathyroidism: a \u201cforme fruste\u201d of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613322757800_R4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-114-7-593","article-title":"National Institutes of Health Conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement.","volume":"114","year":"1991","journal-title":"Ann Intern Med"},{"key":"2020071613322757800_R5","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1210\/jc.2002-021370","article-title":"Summary statement from a workshop on asymptomatic primay hyperparathyroidism: a perspective for the 21st century","volume":"87","author":"Bilezikian","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613322757800_R6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","article-title":"Increased biochemical markers of bone formation ans resorption in primary hyperparathyroidism with special reference with mild disease","volume":"243","author":"Valdemarsson","year":"1998","journal-title":"J Intern Med"},{"key":"2020071613322757800_R7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/eje.0.1480597","article-title":"Influence of renal function on clinico-pathological features of primary hyperparathyroidism","volume":"148","author":"Yamashita","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071613322757800_R8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1046\/j.1365-2362.1998.00387.x","article-title":"Death risk factor analysis in primary hyperparathyroidism","volume":"28","author":"Hedback","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"2020071613322757800_R9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1046\/j.1365-2362.2001.00926.x","article-title":"The improvement of renal concentration capacity after surgery for primary hyperparathyroidism","volume":"31","author":"Hedback","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"2020071613322757800_R10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1365-2796.2002.00984.x","article-title":"Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism","volume":"25","author":"Hedback","year":"2002","journal-title":"J Intern Med"},{"key":"2020071613322757800_R11","first-page":"110","article-title":"New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation","volume":"82","author":"Fulton","year":"1999","journal-title":"Med Health RI"},{"key":"2020071613322757800_R12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract"},{"key":"2020071613322757800_R13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"2020071613322757800_R14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockroft","year":"1976","journal-title":"Nephron"},{"key":"2020071613322757800_R15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1359\/jbmr.2002.17.12.2094","article-title":"Pathophisiology and recent advances in the management of renal osteodystrophy","volume":"17","author":"Elder","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071613322757800_R16","doi-asserted-by":"crossref","first-page":"F367","DOI":"10.1152\/ajprenal.00061.2002","article-title":"Mechanisms of secondary hyperparathyroidism","volume":"283","author":"Silver","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020071613322757800_R17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","article-title":"Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure","volume":"56","author":"Rix","year":"1999","journal-title":"Kidney Int"},{"key":"2020071613322757800_R18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1046\/j.1523-1755.2002.00306.x","article-title":"Bone mineral density is not diminished by mild to moderate chronic renal insufficiency","volume":"61","author":"Hsu","year":"2002","journal-title":"Kidney Int"},{"key":"2020071613322757800_R19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP63119","article-title":"Cellular and molecular mechanisms of secondary hyperparathyroidism","volume":"63","author":"Silver","year":"2005","journal-title":"Clin Nephrol"},{"key":"2020071613322757800_R20","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118701","article-title":"Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro","volume":"97","author":"Slatopolsky","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071613322757800_R21","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr Rev"},{"key":"2020071613322757800_R22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00198-005-1894-4","article-title":"Guidelines for the management of osteoporosis: the present and the future","volume":"16","author":"Compston","year":"2005","journal-title":"Osteoporos Int"},{"key":"2020071613322757800_R23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1297-319X(00)00240-2","article-title":"Bone status in primary hyperparathyroidism","volume":"68","author":"Chappard","year":"2001","journal-title":"Joint Bone Spine"},{"key":"2020071613322757800_R24","first-page":"173","article-title":"Primary hyperparathyroidism: pathophysiology and impact on bone","volume":"163","author":"Khan","year":"2000","journal-title":"CMAJ"},{"key":"2020071613322757800_R25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/17.2.233","article-title":"Serum osteoprotegerin and renal osteodystrophy","volume":"17","author":"Coen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2020071613322757800_R26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ki.1992.22","article-title":"Free and total 1,25-OH2D levels in subjects with renal disease","volume":"41","author":"Koenig","year":"1992","journal-title":"Kidney Int"},{"key":"2020071613322757800_R27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0272-6386(95)90541-3","article-title":"Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited","volume":"25","author":"Llach","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2020071613322757800_R28","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1046\/j.1523-1755.63.s84.12.x","article-title":"Endothelial dysfunction and inflammation: what is the link","volume":"84","author":"Galle","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"2020071613322757800_R29","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.ASN.0000132474.50966.DA","article-title":"Endothelial dysfunction","volume":"15","author":"Endemann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2020071613322757800_R30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00223-002-2100-8","article-title":"Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism","volume":"73","author":"Stilgren","year":"2003","journal-title":"Caclcif Tissue Int"},{"key":"2020071613322757800_R31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","article-title":"Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-\u03baB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism","volume":"35","author":"Stilgren","year":"2004","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/8\/3011\/10442640\/jcem3011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/8\/3011\/10442640\/jcem3011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:04:45Z","timestamp":1594944285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/91\/8\/3011\/2656504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2006-0070","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}